A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma

雷莫芦单抗和紫杉醇/扎尼达单抗治疗 HER2 过表达晚期胃食管腺癌的随机 II 期研究

• 批准号: 474607
• 负责人: Elimova Elena
• 金额: $ 54.56万
• 依托单位: Queen's University (Kingston, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-07-01 至 2025-07-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=474607&lang=en
• 关键词: Clinical Trial; Gastroesophageal Cancer; Her 2 Positive

Patients with advanced stomach or esophageal cancer that is not treatable by surgical removal and which has high amounts of human epidermal growth factor receptor Type 2 (aka HER2) on the surface of their tumour cells, receive the anti-HER2 drug trastuzum

晚期胃癌或食管癌患者不能通过手术切除治疗，并且在其肿瘤细胞表面具有大量的人表皮生长因子受体2（又名HER2），接受抗HER2药物曲妥珠单抗